Original Articles

You have full text access to this OnlineOpen article

Conivaptan increases serum sodium in hyponatremic patients with end-stage liver disease

  1. Jacqueline G. O'Leary†,*,
  2. Gary L. Davis

Article first published online: 29 SEP 2009

DOI: 10.1002/lt.21836

Issue

Liver Transplantation

Liver Transplantation

Volume 15, Issue 10, pages 1325–1329, October 2009

Additional Information

How to Cite

O'Leary, J. G. and Davis, G. L. (2009), Conivaptan increases serum sodium in hyponatremic patients with end-stage liver disease. Liver Transpl, 15: 1325–1329. doi: 10.1002/lt.21836

Author Information

  1. Division of Hepatology, Department of Medicine, Baylor University Medical Center, Dallas, TX

  1. †

    Telephone: 214-820-8500; FAX: 214-820-8168

*Baylor University Medical Center, 4th Floor Roberts Building, 3500 Gaston Avenue, Dallas, TX 75246

Publication History

  1. Issue published online: 29 SEP 2009
  2. Article first published online: 29 SEP 2009
  3. Manuscript Accepted: 11 MAY 2009
  4. Manuscript Received: 18 NOV 2008

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (165K)

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Marcus R. Lenk, Michael Kaspar, Sodium-reduced continuous venovenous hemodiafiltration (CVVHDF) for the prevention of central pontine myelinolysis (CPM) in hyponatremic patients scheduled for orthotopic liver transplantation, Journal of Clinical Anesthesia, 2012,

    CrossRef

  2. 2
    Andrés Cárdenas, Pere Ginès, Paul Marotta, Frank Czerwiec, John Oyuang, Mónica Guevara, Nezam H Afdhal, Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis, Journal of Hepatology, 2012, 56, 3, 571

    CrossRef

  3. 3
    Joao Felipe de Brito Galvao, Sharon A. Center, Fluid, Electrolyte, and Acid-Base Disorders in Small Animal Practice, 2012,

    CrossRef

  4. 4
    Ramakrishnan Arulraj, James Neuberger, Blumgart's Surgery of the Liver, Pancreas and Biliary Tract, 2012,

    CrossRef

  5. 5
    Milap Pokaharel, Clay A. Block, Dysnatremia in the ICU, Current Opinion in Critical Care, 2011, 17, 6, 581

    CrossRef

  6. 6
    Elwaleed A Elhassan, Robert W Schrier, Hyponatremia: diagnosis, complications, and management including V2 receptor antagonists, Current Opinion in Nephrology and Hypertension, 2011, 20, 2, 161

    CrossRef

  7. 7
    Elwaleed A Elhassan, Robert W Schrier, The use of vasopressin receptor antagonists in hyponatremia, Expert Opinion on Investigational Drugs, 2011, 20, 3, 373

    CrossRef

  8. 8
    Gary L. Robertson, Vaptans for the treatment of hyponatremia, Nature Reviews Endocrinology, 2011, 7, 3, 151

    CrossRef

  9. 9
    EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis, Journal of Hepatology, 2010, 53, 3, 397

    CrossRef

  10. 10
    Michael E. Sughrue, Michael McDermott, Lewis S. Blevins, Extreme correction of hyponatremia in a patient treated with intravenous conivaptan, Journal of Clinical Neuroscience, 2010, 17, 10, 1331

    CrossRef

  11. 11
    Elsa Solà, Pere Ginès, Renal and circulatory dysfunction in cirrhosis: Current management and future perspectives, Journal of Hepatology, 2010, 53, 6, 1135

    CrossRef

  12. 12
    Mark T Keegan, David R Wright, Sodium, potassium and glucose management in organ transplantation, Current Opinion in Organ Transplantation, 2010, 15, 3, 383

    CrossRef

  13. 13
    Richard H Sterns, John Kevin Hix, Stephen Silver, Treatment of hyponatremia, Current Opinion in Nephrology and Hypertension, 2010, 19, 5, 493

    CrossRef

  14. 14
    Andrés Cárdenas, Pere Ginès, Ascites and hepatorenal syndrome,
    Direct Link:
View Full Article (HTML) Get PDF (165K)